DDRE-24. ACQUIRED RESISTANCE TO TARGETED INHIBITORS IN EGFR-DRIVEN GLIOBLASTOMA: IDENTIFICATION OF DUAL KINASE TARGETS

Glioblastoma (GBM) is a devastating primary brain tumor with 5-year survival < 5%. CDKN2A deletion (~60%) and EGFR amplification (55–60%) mutations frequently co-occur in these tumors. EGFR is an attractive therapeutic target due to its mutational frequency and availability of multiple brain-pene...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Shelton, Abigail, Smithberger, Erin, Butler, Madison, Stamper, Allie, Bash, Ryan, Angus, Steven, East, Mike, Johnson, Gary, Berens, Michael, Furnari, Frank, Miller, C Ryan
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Drug Discovery, Drug Resistance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650974/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.269
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars